GlassScriptPhysician profile
Kelly Sisson
NPI 1225604093
$1,735.98
in general payments reported to CMS, 2019-2025
20 companies · $978 in 2025
The $978 reported for 2025 was more than what 87% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.66 · 2023: $239 · 2024: $421 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,638.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $258.50 | 2024-2025 | Micra |
| Abiomed | $191.67 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $189.08 | 2025 | |
| Abbott Laboratories | $182.59 | 2024 | Mitraclip |
| Boston Scientific Corporation | $153.37 | 2025 | Watchman Access System, General - Therapies |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.63 | 2022-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $110.94 | 2024 | Assure Wcd |
| Biotronik INC. | $79.00 | 2023 | Acticor 7 Vr-T Dx |
| Cvrx, INC. | $70.92 | 2023-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $65.74 | 2025 | Amvuttra |
| Amgen INC. | $59.48 | 2025 | Repatha |
| Novo Nordisk INC | $49.57 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $45.14 | 2025 | Attruby |
| Lantheus Medical Imaging, INC. | $41.44 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.47 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.53 | 2025 | Wainua |
| Lilly USA, LLC | $21.62 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $19.90 | 2025 | Camzyos |
| Pfizer INC. | $15.50 | 2025 | |
| Altathera Pharmaceuticals LLC | $9.89 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Sisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.